Three Dosing Schedules of Oral Rigosertib in MDS Patients
This study will compare the dosing regimen of oral rigosertib, which has been used in other studies of lower risk Myelodysplastic Syndrome (MDS), with 2 new dosing regimens to determine if one of the new regimens gives improved results as measured by disease status, side effects, and analyses of blood and urine samples.
Inclusion Criteria
- Diagnosis of MDS according to World Health Organization (WHO) criteria or French-American-British (FAB) classification that must be confirmed by bone marrow (BM) aspirate and/or biopsy within 6 weeks prior to Screening.
- MDS classified as Low-risk or Int-1 risk or Int-2 risk according to International Prognostic Scoring System (IPSS) classification; in addition, patients should never have been classified as High-risk since their MDS was diagnosed.
- Transfusion dependency defined by transfusion of at least 4 units of RBC (red blood cells) within 8 weeks before Screening; pre-transfusion Hgb (hemoglobin) values must be ≤ 9 g/dL to be taken into account.
- Refractory to 8- to 12-week course of ESA (erythropoiesis stimulating agent) administered within the past 2 years before enrollment, or erythropoietin (EPO) level ˃ 500 mU/mL and off ESA for at least 8 weeks before Screening.
- Off all other treatments for MDS for at least 2 weeks prior to Screening.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
- Willing to adhere to the prohibitions and restrictions specified in the protocol.
- The patient must signed an informed consent form (ICF).
Exclusion Criteria
- Ongoing clinically significant anemia due to factors such as iron, vitamin B12, or folate deficiencies, auto-immune or hereditary hemolysis, or gastrointestinal bleeding.
- Serum ferritin < 50 ng/mL.
- Hypoplastic MDS (cellularity < 10%).
- Any active malignancy within the past year, except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast.
- Uncontrolled intercurrent illness.
- Active infection not adequately responding to appropriate therapy.
- Total bilirubin ≥ 2.0 mg/dL not related to hemolysis or Gilbert's disease.
- Alanine transaminase (ALT) or aspartate transaminase (AST) ≥ 2.5 x the upper limit of normal (ULN).
- Serum creatinine ≥ 2.0 mg/dL.
- Ascites requiring active medical management including paracentesis.
- Hyponatremia (defined as serum sodium value of < 130 mEq/L).
- Female patients of child-bearing potential or male patients with partners of child-bearing potential who are unwilling to follow strict contraception requirements before entry and throughout the study, up to and including the 30-day non-treatment follow-up period.
- Female patients with reproductive potential who do not have a negative blood or urine pregnancy test at Screening or who are lactating.
- Major surgery without full recovery or major surgery within 3 weeks of Screening.
- Uncontrolled hypertension (defined as a systolic pressure ≥ 160 mmHg and/or a diastolic pressure ≥ 110 mmHg).
- New onset seizures (within 3 months prior to the first dose of rigosertib) or poorly controlled seizures.
- Any other concurrent chemotherapy, radiotherapy, or immunotherapy.
- Chronic use (˃ 2 weeks) of corticosteroids (˃ 10 mg/24 hour equivalent prednisone) within 4 weeks of Baseline/Cycle 1 Day 1 visit.
- Investigational therapy within 4 weeks of Screening.
- Psychiatric illness or social situation that would limit the patient's ability to tolerate and/or comply with study requirements.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02075034.
This will be a Phase I, randomized, 3-treatment arm, single-center study in
transfusion-dependent Myelodysplastic Syndrome (MDS) patients classified as Low- or
Intermediate-1 (Int-1) or Intermediate-2 (Int-2) risk by the International Prognostic
Scoring System (IPSS). Initially, 18 patients (6 per treatment arm) will be randomized in
a 1:1:1 ratio to 1 of 3 oral rigosertib dosing regimens, each of which is a cycle
consisting of 14 consecutive days of dosing followed by 7 days off drug.
Treatment with erythropoiesis-stimulating agent (ESA) is prohibited for the first 15
weeks (5 cycles). After 15 weeks of dosing (5 cycles), ESA treatment will be initiated if
the patient still needs red blood cell (RBC) transfusions and if the pre-transfusion
hemoglobin (Hgb) value is ≤ 9 g/dL, unless the clinical judgment of the Investigator
determines ESA administration to a patient with a Hgb level > 9 g/dL is warranted.
All study participants will be allowed, as medically justified, access to RBC and
platelet (PLT) transfusions, and to filgrastim. Rigosertib dosing adjustment policies are
described.
After all 18 patients have completed 3 cycles, a risk/benefit analysis will be completed
assessing the distribution of adverse events (AEs) and serious adverse events (SAEs) and
the number of transfusions among the 3 treatment arms. This analysis will select 1 of the
3 dosing regimens as having the best risk/benefit profile and an additional 12 to 18
patients will be enrolled at this dosing regimen. Eligibility criteria may be modified by
protocol amendments to enroll patients with different characteristics. All patients will
be treated for 48 weeks or until 2006 International Working Group (IWG) progression
criteria are met, unacceptable toxicity is observed, intercurrent illness or a change in
the patient's condition prevents further administration of study drug treatment, or until
death from any cause occurs, whichever comes first. Patients who have continued
hematologic response at 48 weeks may continue to be treated in the study beyond 48 weeks
until 2006 IWG progression criteria are met or until death from any cause, whichever
comes first.
Trial PhasePhase I
Trial Typetreatment
Lead OrganizationTraws Pharma, Inc.
- Primary IDOnconova 09-10
- Secondary IDsNCI-2015-00738
- ClinicalTrials.gov IDNCT02075034